1. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options 
Axel C. Mühlbacher, PhD, Andrew Sadler, MSc 
Value in Health 
Volume 20, Issue 2, Pages (February 2017)
DOI: /j.jval
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Efficiency frontier model of therapy-naive patients. A: Harvoni (LDV + SOF) 8 wk; B: Harvoni (LDV + SOF) 12 wk; C: Viekirax/Exviera (OBV/PTV/r + DSV ± RBV) 12 wk; D: Daklinza (DAC + SOF) 12 wk; E: Daklinza (DAC + SOF + RBV) 12 wk; F: Olysio (SIM + PEG + RBV) 24 wk; G: Sovaldi (SOF + PEG + RBV) 12 wk; H: Victrelis (BOC + PEG + RBV) 38 wk, 34 with BOC; I: Incivo (TLV + PEG + RBV) 48 wk, 12 with TLV; J: PEG-IFN-α-2a/2b/RBV 48 wk. BOC, boceprevir; DAC, daclatasvir; DSV, dasapuvir; LDV, ledipasvir; OBV, ombitasvir; PEG-IFN, pegylated interferon; PTV/r, paritaprevir/ritonavir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; TLV, telaprevir.
Value in Health  , DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
NMB for Harvoni 8 wk (model of therapy-naive patients). IQR, interquartile range; NMB, net monetary benefit.
Value in Health  , DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
PAC for Harvoni 8 wk (model of therapy-naive patients). PAC, price acceptability curve.
Value in Health  , DOI: ( /j.jval )
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions